Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarketing Requirement Increases In EU May Be Enforced By Fines

Executive Summary

The European Commission may use fines to enforce increased postmarketing reporting requirements.

You may also be interested in...



Scios/Quintiles Natrecor Deal Includes Funding, Sales Support

Scios will provide incentives to Innovex for getting its acute decompensated congestive heart failure treatment Natrecor approved for hospital formularies as part of a marketing agreement with Quintiles.

Biotechnology's "C"-Saw Year: Cialis Boosts Icos, Coviracil Costs Triangle

Icos' upcoming NDA filing for the erectile dysfunction agent Cialis looks like the kind of new product milestone that is playing well with biotech investors heading into 2001.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel